Anti-inflammatory signaling in schizophrenia

A great deal of interest has been centered upon activated inflammatory processes in schizophrenia and their contribution to disease-relevant brain and behavioral impairment. In contrast, the role of anti-inflammatory signaling has attracted somewhat less attention in this context. The present article focuses on the emerging role of anti-inflammatory signaling in schizophrenia and discusses the potential influence of altered anti-inflammatory activity on progressive inflammatory processes, physical and metabolic functions, and treatment effects related to the use of conventional antipsychotic drugs and immunomodulatory agents in the pharmacotherapy of schizophrenia. By reviewing existing evidence, it appears that enhanced anti-inflammatory activity has many faces in schizophrenia: On the one hand, it may effectively limit potentially harmful inflammatory processes and may contribute to the improvement of psychopathological symptoms, especially when the anti-inflammatory system is boosted at early stages of the disease. On the other hand, enhanced anti-inflammatory activity may render affected individuals more susceptible to distinct physiological abnormalities such as cardiovascular disease, and may further impede the resistance to specific infectious agents. Therefore, an enhancement of anti-inflammatory signaling in schizophrenia might not simply be said to be either advantageous or disadvantageous, but rather should be interpreted and dealt with in a context-dependent manner. Increased awareness of the multiple roles of anti-inflammatory signaling may readily help to reduce additional health burdens in schizophrenia, and at the same time, may provide opportunities to further explore the benefits associated with anti-inflammatory strategies in the symptomatological and/or preventive treatment of this disorder.

[1]  Yong-Ku Kim,et al.  Monocytic, Th1 and Th2 Cytokine Alterations in the Pathophysiology of Schizophrenia , 2007, Neuropsychobiology.

[2]  P. Falkai,et al.  Evidence for activation of microglia in patients with psychiatric illnesses , 1999, Neuroscience Letters.

[3]  R. Schwarcz,et al.  Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in Schizophrenia. , 2010, Schizophrenia bulletin.

[4]  K. Morley,et al.  Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis. , 2011, Archives of general psychiatry.

[5]  Manuel Desco,et al.  Ventricular enlargement in schizophrenia is associated with a genetic polymorphism at the interleukin-1 receptor antagonist gene , 2005, NeuroImage.

[6]  M. Schwarz,et al.  The Immune System and Schizophrenia: An Integrative View , 2000, Annals of the New York Academy of Sciences.

[7]  R. Kahn,et al.  Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. , 2010, The Journal of clinical psychiatry.

[8]  A. Sher,et al.  In the absence of endogenous IFN-gamma, mice develop unimpaired IL-12 responses to Toxoplasma gondii while failing to control acute infection. , 1996, Journal of immunology.

[9]  Mika P Tarvainen,et al.  Heart rate variability in acute psychosis. , 2003, Psychophysiology.

[10]  H. Bessler,et al.  Effect of neuroleptic administration on serum levels of soluble IL-2 receptor-alpha and IL-1 receptor antagonist in schizophrenic patients , 2005, Psychiatry Research.

[11]  H. Möller,et al.  Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. , 2002, The American journal of psychiatry.

[12]  P. Collins,et al.  Fever and acute brief psychosis in urban and rural settings in north India , 1999, British Journal of Psychiatry.

[13]  R. Yolken,et al.  Toxoplasma gondii and Schizophrenia , 2003, Emerging infectious diseases.

[14]  M. Iyo,et al.  A decrease in interleukin-1 receptor antagonist expression in the prefrontal cortex of schizophrenic patients , 2003, Neuroscience Research.

[15]  H. Meltzer,et al.  Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: effects of antipsychotic drugs , 1996, Schizophrenia Research.

[16]  P. Abreu,et al.  Interleukin‐1β stimulates tyrosine hydroxylase activity in the median eminence , 1994 .

[17]  L. Garey.  When cortical development goes wrong: schizophrenia as a neurodevelopmental disease of microcircuits , 2010, Journal of anatomy.

[18]  Charles R. Yang,et al.  Allosteric modulation of NMDA receptor via elevation of brain glycine and D-serine: the therapeutic potentials for schizophrenia. , 2008, Pharmacology & therapeutics.

[19]  Herng‐Ching Lin,et al.  Increased Risk of Acute Myocardial Infarction After Acute Episode of Schizophrenia: 6 Year Follow-Up Study , 2010, The Australian and New Zealand journal of psychiatry.

[20]  B. Bogerts,et al.  Acute schizophrenia is accompanied by reduced T cell and increased B cell immunity , 2010, European Archives of Psychiatry and Clinical Neuroscience.

[21]  M. Schwarz,et al.  Kynurenine pathway in schizophrenia: pathophysiological and therapeutic aspects. , 2011, Current pharmaceutical design.

[22]  C. Pantelis,et al.  Stress, the Hippocampus and the Hypothalamic-Pituitary-Adrenal Axis: Implications for the Development of Psychotic Disorders , 2006 .

[23]  G. Aghajanian,et al.  The role of serotonin in the pathophysiology and treatment of schizophrenia. , 1997, The Journal of neuropsychiatry and clinical neurosciences.

[24]  Hans-Jürgen Möller,et al.  Clinical evaluation of negative symptoms in schizophrenia , 2007, European Psychiatry.

[25]  John M Davis,et al.  Physical health monitoring of patients with schizophrenia. , 2004, The American journal of psychiatry.

[26]  M. Vawter,et al.  Transforming Growth Factors β1 and β2 in the Cerebrospinal Fluid of Chronic Schizophrenic Patients , 1997, Neuropsychopharmacology.

[27]  M. Popoli,et al.  Association between promoter polymorphic haplotypes of interleukin-10 gene and schizophrenia , 2002, Biological Psychiatry.

[28]  Y. Levkovitz,et al.  A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. , 2010, The Journal of clinical psychiatry.

[29]  D. Wakefield,et al.  Increased production of interleukin-2 (IL-2) but not soluble interleukin-2 receptors (sIL-2R) in unmedicated patients with schizophrenia and schizophreniform disorder , 1996, Psychiatry Research.

[30]  S. Humphreys,et al.  Increased weight loss with reduced viral replication in interleukin‐10 knock‐out mice infected with murine cytomegalovirus , 2007, Clinical and experimental immunology.

[31]  J. Flory,et al.  Interleukin-6 Covaries Inversely With Cognitive Performance Among Middle-Aged Community Volunteers , 2006, Psychosomatic medicine.

[32]  J. Suvisaari,et al.  Coronary heart disease and cardiac conduction abnormalities in persons with psychotic disorders in a general population , 2010, Psychiatry Research.

[33]  M. Schwarz,et al.  Immune System and Schizophrenia. , 2010, Current immunology reviews.

[34]  Emmanuel Stip,et al.  Inflammatory Cytokine Alterations in Schizophrenia: A Systematic Quantitative Review , 2008, Biological Psychiatry.

[35]  L. Jarskog,et al.  Apoptosis in schizophrenia: pathophysiologic and therapeutic considerations , 2006, Current opinion in psychiatry.

[36]  A Carlsson,et al.  Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. , 2001, Annual review of pharmacology and toxicology.

[37]  R. Dantzer,et al.  From inflammation to sickness and depression: when the immune system subjugates the brain , 2008, Nature Reviews Neuroscience.

[38]  L. Qi,et al.  Superoxide dismutase and cytokines in chronic patients with schizophrenia: association with psychopathology and response to antipsychotics , 2009, Psychopharmacology.

[39]  L. Garey,et al.  Increase in HLA‐DR Immunoreactive Microglia in Frontal and Temporal Cortex of Chronic Schizophrenics , 2000, Journal of neuropathology and experimental neurology.

[40]  Jeffrey K. Yao,et al.  Elevated interleukin-6 in schizophrenia , 1999, Psychiatry Research.

[41]  H. Anisman,et al.  Sensitization to the neuroendocrine, central monoamine and behavioural effects of murine tumor necrosis factor‐α: peripheral and central mechanisms , 2002, The European journal of neuroscience.

[42]  N. Arakawa,et al.  Elevated plasma levels of interleukin-1 receptor antagonist and interleukin-10 in patients with acute myocardial infarction. , 1997, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[43]  M. Cuénod,et al.  Redox dysregulation, neurodevelopment, and schizophrenia , 2009, Current Opinion in Neurobiology.

[44]  H. Kalant,et al.  Adverse effects of cannabis on health: an update of the literature since 1996 , 2004, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[45]  H. Critchley,et al.  Peripheral Inflammation is Associated with Altered Substantia Nigra Activity and Psychomotor Slowing in Humans , 2008, Biological Psychiatry.

[46]  J. O’Shea,et al.  Cytokine signaling modules in inflammatory responses. , 2008, Immunity.

[47]  A. Dunn,et al.  Behavioral Effects of Cytokines , 2001, Brain, Behavior, and Immunity.

[48]  Reto Meuli,et al.  Glutathione Precursor, N-Acetyl-Cysteine, Improves Mismatch Negativity in Schizophrenia Patients , 2008, Neuropsychopharmacology.

[49]  D. Hinze‐Selch,et al.  A controlled prospective study of toxoplasma gondii infection in individuals with schizophrenia: beyond seroprevalence. , 2007, Schizophrenia bulletin.

[50]  D. Lewis,et al.  Cortical inhibitory neurons and schizophrenia , 2005, Nature Reviews Neuroscience.

[51]  U. Müller-Ladner,et al.  Actual status of antiinterleukin-1 therapies in rheumatic diseases , 2010, Current opinion in rheumatology.

[52]  M. Holtze,et al.  Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. , 2012, Schizophrenia bulletin.

[53]  M. Schwarz,et al.  Soluble IL-6 receptors in the serum and cerebrospinal fluid of paranoid schizophrenic patients , 1997, European Psychiatry.

[54]  B. Leonard,et al.  Th1, Th2 and Th3 cytokine alteration in schizophrenia , 2004, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[55]  H. Kornhuber,et al.  T-lymphocyte subpopulations in schizophrenic patients , 2005, European archives of psychiatry and neurological sciences.

[56]  Pat Levitt,et al.  Molecular Evidence for Increased Expression of Genes Related to Immune and Chaperone Function in the Prefrontal Cortex in Schizophrenia , 2007, Biological Psychiatry.

[57]  B. Baune,et al.  Evidence for a cytokine model of cognitive function , 2009, Neuroscience & Biobehavioral Reviews.

[58]  D. Goff,et al.  Inflammation and schizophrenia , 2007, Expert review of neurotherapeutics.

[59]  D. Greaves,et al.  Autocrine Deactivation of Macrophages in Transgenic Mice Constitutively Overexpressing IL-10 Under Control of the Human CD68 Promoter1 , 2002, The Journal of Immunology.

[60]  X. Zhang,et al.  Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology , 2002, Schizophrenia Research.

[61]  Takahiro A. Kato,et al.  Cytokines and schizophrenia: Microglia hypothesis of schizophrenia , 2009, Psychiatry and clinical neurosciences.

[62]  Y. Mitsumoto,et al.  Atypical antipsychotics suppress production of proinflammatory cytokines and up-regulate interleukin-10 in lipopolysaccharide-treated mice , 2009, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[63]  M. Schwarz,et al.  Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia , 2008, European Archives of Psychiatry and Clinical Neuroscience.

[64]  D. Bucci,et al.  Increased concentration of cerebral kynurenic acid alters stimulus processing and conditioned responding , 2006, Behavioural Brain Research.

[65]  H. Knüpfer,et al.  sIL‐6R: more than an agonist? , 2008, Immunology and cell biology.

[66]  H. Meltzer,et al.  In vivo immunomodulatory effects of clozapine in schizophrenia , 1997, Schizophrenia Research.

[67]  M. Ackenheil,et al.  Cellular immunity in schizophrenic patients before and during neuroleptic treatment , 1991, Psychiatry Research.

[68]  W. Nolen,et al.  An activated set point of T-cell and monocyte inflammatory networks in recent-onset schizophrenia patients involves both pro- and anti-inflammatory forces. , 2011, The international journal of neuropsychopharmacology.

[69]  Jianxin Shi,et al.  Common variants on chromosome 6p22.1 are associated with schizophrenia , 2009, Nature.

[70]  M. Block,et al.  Microglia-mediated neurotoxicity: uncovering the molecular mechanisms , 2007, Nature Reviews Neuroscience.

[71]  R. Young,et al.  T cell-derived IL-10 antagonizes macrophage function in mycobacterial infection. , 1997, Journal of immunology.

[72]  A. Patruno,et al.  Dysregulation of chemo-cytokine production in schizophrenic patients versus healthy controls , 2011, BMC Neuroscience.

[73]  H. Young,et al.  Cytokines as critical co-stimulatory molecules in modulating the immune response of natural killer cells , 2006, Cell Research.

[74]  Jing-ping Zhao,et al.  The Interaction of Nuclear Factor-Kappa B and Cytokines Is Associated with Schizophrenia , 2009, Biological Psychiatry.

[75]  A. Dunn.  Effects of cytokines and infections on brain neurochemistry , 2006, Clinical Neuroscience Research.

[76]  W. Arend.  The balance between IL-1 and IL-1Ra in disease. , 2002, Cytokine & growth factor reviews.

[77]  R. Yolken,et al.  Are some cases of psychosis caused by microbial agents? A review of the evidence , 2008, Molecular Psychiatry.

[78]  M. Beary,et al.  Are there modifiable risk factors which will reduce the excess mortality in schizophrenia? , 2010, Journal of psychopharmacology.

[79]  D. Weinberger.  Implications of normal brain development for the pathogenesis of schizophrenia. , 1987, Archives of general psychiatry.

[80]  R. Boellaard,et al.  Microglia Activation in Recent-Onset Schizophrenia: A Quantitative (R)-[11C]PK11195 Positron Emission Tomography Study , 2008, Biological Psychiatry.

[81]  D. Eyles,et al.  The neurodevelopmental hypothesis of schizophrenia: convergent clues from epidemiology and neuropathology. , 2012, The Psychiatric clinics of North America.

[82]  M. Clerici,et al.  Cytokine profiles in schizophrenic patients treated with risperidone A 3-month follow-up study , 2002, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[83]  B. Nelson,et al.  Biology of the interleukin-2 receptor. , 1998, Advances in immunology.

[84]  M. Schwarz,et al.  T- and B-lymphocytes in patients with schizophrenia in acute psychotic episode and the course of the treatment , 2007, Psychiatry Research.

[85]  R. Pioli,et al.  Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor , 2002, Schizophrenia Research.

[86]  P. Murray.  Understanding and exploiting the endogenous interleukin-10/STAT3-mediated anti-inflammatory response. , 2006, Current opinion in pharmacology.

[87]  Henry A. Nasrallah,et al.  Schizophrenia, “Just the Facts” What we know in 2008. 2. Epidemiology and etiology , 2008, Schizophrenia Research.

[88]  Pall I. Olason,et al.  Common variants conferring risk of schizophrenia , 2009, Nature.

[89]  Z. Herman,et al.  Cytokines in schizophrenia and the effects of antipsychotic drugs , 2006, Brain, Behavior, and Immunity.

[90]  John I. Gallin,et al.  Inflammation: Basic Principles and Clinical Correlates , 1992 .

[91]  B. Bogerts,et al.  Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. , 2008, Journal of psychiatric research.

[92]  M. Subramaniam,et al.  Metabolic risk factors in drug-naive patients with first-episode psychosis. , 2009, The Journal of clinical psychiatry.

[93]  Kenichi Yamamoto,et al.  Proposal for a noradrenaline hypothesis of schizophrenia , 2004, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[94]  M. Keshavan,et al.  Beat-to-beat heart rate and QT interval variability in first episode neuroleptic-naive psychosis , 2009, Schizophrenia Research.

[95]  I. Melle,et al.  Similar immune profile in bipolar disorder and schizophrenia: selective increase in soluble tumor necrosis factor receptor I and von Willebrand factor. , 2009, Bipolar disorders.

[96]  H. Y. Meltzer,et al.  Immune‐inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine , 1994, Acta psychiatrica Scandinavica.

[97]  T. Miyaoka.  Clinical potential of minocycline for schizophrenia. , 2008, CNS & neurological disorders drug targets.

[98]  F. Dickerson,et al.  C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia , 2007, Schizophrenia Research.

[99]  S. Kapur,et al.  The dopamine hypothesis of schizophrenia: version III--the final common pathway. , 2009, Schizophrenia bulletin.

[100]  T. Pollmächer,et al.  Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. , 1999, Journal of psychiatric research.

[101]  P. McKenna,et al.  Altered T-Cell Function in Schizophrenia: A Cellular Model to Investigate Molecular Disease Mechanisms , 1996, PloS one.

[102]  M. Keshavan,et al.  3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia. , 2011, The international journal of neuropsychopharmacology.

[103]  Yu Wakabayashi,et al.  Cellular and molecular basis for the regulation of inflammation by TGF-beta. , 2010, Journal of biochemistry.

[104]  John Savill,et al.  Resolution of inflammation: the beginning programs the end , 2005, Nature Immunology.

[105]  B. Kirkpatrick,et al.  Metabolic profile of antipsychotic-naive individuals with non-affective psychosis , 2009, British Journal of Psychiatry.

[106]  E. Bosmans,et al.  Immunosuppressive effects of clozapine and haloperidol: enhanced production of the interleukin-1 receptor antagonist , 2000, Schizophrenia Research.

[107]  M. Keshavan,et al.  Schizophrenia, “just the facts” 4. Clinical features and conceptualization , 2009, Schizophrenia Research.

[108]  William E. Greineisen,et al.  Immunoactive effects of cannabinoids: considerations for the therapeutic use of cannabinoid receptor agonists and antagonists. , 2010, International immunopharmacology.

[109]  P. Ghazal,et al.  Hijacking and exploitation of IL-10 by intracellular pathogens. , 2001, Trends in microbiology.

[110]  J. Rawlins,et al.  The neuropsychology of schizophrenia , 1991, Behavioral and Brain Sciences.

[111]  M. Teixeira,et al.  Increased Serum Levels of Inflammatory Markers in Chronic Institutionalized Patients with Schizophrenia , 2008, Neuroimmunomodulation.

[112]  H. Ombao,et al.  Plasma cytokine concentrations associated with HIV/hepatitis C coinfection are related to attention, executive and psychomotor functioning , 2011, Journal of Neuroimmunology.

[113]  M. Rothermundt,et al.  S100B in schizophrenia: an update. , 2009, General physiology and biophysics.

[114]  M. Schulzer,et al.  At issue: schizophrenia and rheumatoid arthritis: the negative association revisited. , 1999, Schizophrenia bulletin.

[115]  Liang Liu,et al.  Tyrosine hydroxylase, interleukin-1β and tumor necrosis factor-α are overexpressed in peripheral blood mononuclear cells from schizophrenia patients as determined by semi-quantitative analysis , 2010, Psychiatry Research.

[116]  R. Pioli,et al.  The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6 , 1998, Schizophrenia Research.

[117]  T. Goldberg,et al.  Cognitive impairment in schizophrenia is the core of the disorder. , 2000, Critical reviews in neurobiology.

[118]  J. Mege,et al.  A differential role for interleukin-6 and tumor necrosis factor-α in schizophrenia? , 1997, Schizophrenia Research.

[119]  H. Hermesh,et al.  Abnormal thermoregulation in drug-free male schizophrenia patients , 2001, European Neuropsychopharmacology.

[120]  H. Yasuda,et al.  Minocycline as Adjunctive Therapy for Schizophrenia: An Open-Label Study , 2008, Clinical neuropharmacology.

[121]  Anneclaire J. De Roos,et al.  Epidemiology and Etiology , 2013 .

[122]  D. Goff,et al.  Converging Evidence of NMDA Receptor Hypofunction in the Pathophysiology of Schizophrenia , 2003, Annals of the New York Academy of Sciences.

[123]  V. Perry,et al.  Microglial physiology: unique stimuli, specialized responses. , 2009, Annual review of immunology.

[124]  X. Zhang,et al.  Cortisol and Cytokines in Chronic and Treatment-Resistant Patients with Schizophrenia: Association with Psychopathology and Response to Antipsychotics , 2005, Neuropsychopharmacology.

[125]  J. Overmier,et al.  Lipopolysaccharide-induced immune activation impairs attention but has little effect on short-term working memory , 2008, Behavioural Brain Research.

[126]  M. Rapaport,et al.  Persistently increased serum soluble interleukin-2 receptors in continuously ill patients with schizophrenia. , 2009, The international journal of neuropsychopharmacology.

[127]  P. Santosh,et al.  Onset of acute psychotic states in India: a study of sociodemographic, seasonal and biological factors , 1998, Acta psychiatrica Scandinavica.

[128]  R. S. Smith.  The immune system is a key factor in the etiology of psychosocial disease. , 1991, Medical hypotheses.

[129]  Lin He,et al.  An association between polymorphisms of the interleukin-10 gene promoter and schizophrenia in the Chinese population , 2004, Schizophrenia Research.

[130]  S. Bauer,et al.  The neuropoietic cytokine family in development, plasticity, disease and injury , 2007, Nature Reviews Neuroscience.

[131]  M. Gershwin,et al.  The regulatory, inflammatory, and T cell programming roles of interleukin-2 (IL-2). , 2008, Journal of autoimmunity.

[132]  Daniel C Javitt,et al.  Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions. , 2007, International review of neurobiology.

[133]  K. Blennow,et al.  Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia , 2005, Schizophrenia Research.

[134]  J. Bradley,et al.  TNF‐mediated inflammatory disease , 2008, The Journal of pathology.

[135]  R. Schwarcz,et al.  The Brain Metabolite Kynurenic Acid Inhibits α7 Nicotinic Receptor Activity and Increases Non-α7 Nicotinic Receptor Expression: Physiopathological Implications , 2001, The Journal of Neuroscience.

[136]  W. Leonard,et al.  Activation of tumor necrosis factor-alpha production from human neutrophils by IL-2 via IL-2-R beta. , 1993, Journal of immunology.

[137]  Rudi A. Dierckx,et al.  Neuroinflammation in Schizophrenia-Related Psychosis: A PET Study , 2009, Journal of Nuclear Medicine.

[138]  R. Schwarcz,et al.  Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia. , 2011, Schizophrenia bulletin.

[139]  Urs Meyer,et al.  Schizophrenia and Autism: Both Shared and Disorder-Specific Pathogenesis Via Perinatal Inflammation? , 2011, Pediatric Research.

[140]  R. Schreiber,et al.  Interferon-gamma: the major mediator of resistance against Toxoplasma gondii. , 1988, Science.

[141]  B. Bogerts,et al.  Glial cells in schizophrenia: pathophysiological significance and possible consequences for therapy , 2009, Expert review of neurotherapeutics.

[142]  C. Gabay,et al.  Interleukin-1 receptor antagonist: role in biology. , 1998, Annual review of immunology.

[143]  H. Anisman,et al.  Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6 , 1994, Brain Research.

[144]  B. Bogerts,et al.  Distribution of HLA-DR-positive microglia in schizophrenia reflects impaired cerebral lateralization , 2006, Acta Neuropathologica.

[145]  Yong-Ku Kim,et al.  Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics , 2000, Schizophrenia Research.

[146]  Norbert Müller,et al.  COX-2 inhibition in schizophrenia and major depression. , 2008, Current pharmaceutical design.

[147]  M. Schwarz,et al.  The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression , 2007, Molecular Psychiatry.

[148]  T. Moore,et al.  Induction of TGF-β1, Not Regulatory T Cells, Impairs Antiviral Immunity in the Lung following Bone Marrow Transplant , 2010, The Journal of Immunology.

[149]  C. Stefanis,et al.  Cytokine serum levels, autologous mixed lymphocyte reaction and surface marker analysis in never medicated and chronically medicated schizophrenic patients , 2001, Schizophrenia Research.

[150]  B. Brandner,et al.  Acute Effects of Ketamine on Memory Systems and Psychotic Symptoms in Healthy Volunteers , 2004, Neuropsychopharmacology.

[151]  Mahmut Bulut,et al.  Beneficial effects of N-acetylcysteine in treatment resistant schizophrenia , 2009, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[152]  M. Schwarz,et al.  Clinical effects of COX–2 inhibitors on cognition in schizophrenia , 2005, European Archives of Psychiatry and Clinical Neuroscience.

[153]  H. Himmerich,et al.  Anti-inflammatory drugs in psychiatry. , 2009, Inflammation & allergy drug targets.

[154]  R. Freedman,et al.  Schizophrenia and the alpha7 nicotinic acetylcholine receptor. , 2007, International review of neurobiology.

[155]  J. Meis,et al.  A primer on cytokines: sources, receptors, effects, and inducers , 1997, Clinical microbiology reviews.

[156]  G. Kemmler,et al.  T-cell subsets in schizophrenia: a comparison between drug-naive first episode patients and chronic schizophrenic patients , 1999, Schizophrenia Research.

[157]  D. Bucci,et al.  Exposure to kynurenic acid during adolescence produces memory deficits in adulthood. , 2012, Schizophrenia bulletin.

[158]  G. He,et al.  Interleukin-10 −1082 promoter polymorphism is associated with schizophrenia in a Han Chinese sib-pair study , 2006, Neuroscience Letters.

[159]  T. Pollmächer,et al.  Effects of antipsychotic drugs on cytokine networks. , 2000, Journal of psychiatric research.

[160]  M. Rapaport,et al.  Celecoxib Augmentation of Continuously Ill Patients with Schizophrenia , 2005, Biological Psychiatry.

[161]  G. Fantuzzi,et al.  Cytokines in Acute Myocardial Infarction: Selective Increase in Circulating Tumor Necrosis Factor, Its Soluble Receptor, and Interleukin‐1 Receptor Antagonist , 1994, Journal of cardiovascular pharmacology.

[162]  S. Akhondzadeh,et al.  Celecoxib as adjunctive therapy in schizophrenia: A double-blind, randomized and placebo-controlled trial , 2007, Schizophrenia Research.

[163]  S. Kapur.  Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. , 2003, The American journal of psychiatry.

[164]  K. Akiyama.  Serum levels of soluble IL-2 receptor α, IL-6 and IL-1 receptor antagonist in schizophrenia before and during neuroleptic administration , 1999, Schizophrenia Research.

[165]  J. Stevens,et al.  Neuropathology of schizophrenia. , 1982, Archives of general psychiatry.

[166]  C. Heldin,et al.  Mechanisms of TGF-beta signaling in regulation of cell growth and differentiation. , 2002, Immunology letters.

[167]  F. Dickerson,et al.  Cytomegalovirus and Schizophrenia , 2006, CNS drugs.

[168]  H. Steinbusch,et al.  Cytokine Changes and Tryptophan Metabolites in Medication-Naïve and Medication-Free Schizophrenic Patients , 2009, Neuropsychobiology.

[169]  H. Anisman,et al.  Further evidence for the depressive effects of cytokines: Anhedonia and neurochemical changes , 2002, Brain, Behavior, and Immunity.

[170]  V. Arolt,et al.  Search for atypical lymphocytes in schizophrenia , 2004, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[171]  D. Bucci,et al.  Elevations of endogenous kynurenic acid produce spatial working memory deficits. , 2007, Schizophrenia bulletin.

[172]  T. Nurmikko,et al.  IL‐10 gene polymorphism and herpesvirus infections , 2003, Journal of medical virology.

[173]  U. Hadding,et al.  Cellular immune reactions directed against Toxoplasma gondii with special emphasis on the central nervous system , 1997, Medical Microbiology and Immunology.

[174]  R. Bhatnagar,et al.  CORRELATION BETWEEN TYROSINE HYDROXYLASE ACTIVITY AND CATECHOLAMINE CONCENTRATION OR TURNOVER IN BRAIN REGIONS 1 , 1977, Journal of neurochemistry.

[175]  T. Suslow,et al.  Memory impairment correlates with increased S100B serum concentrations in patients with chronic schizophrenia , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[176]  H. Silver.  Selective serotonin re-uptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia , 2004, Expert opinion on pharmacotherapy.

[177]  V. Pasceri,et al.  Interleukin‐1 receptor antagonist levels correlate with extent of myocardial loss in patients with acute myocardial infarction , 2005, Clinical cardiology.

[178]  David A Lewis,et al.  Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations. , 2006, Archives of neurology.

[179]  H. Möller,et al.  Celecoxib treatment in an early stage of schizophrenia: Results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment , 2010, Schizophrenia Research.

[180]  Masatoshi Takeda,et al.  TGFBR2 gene expression and genetic association with schizophrenia. , 2008, Journal of psychiatric research.

[181]  J. Leza,et al.  Stress as a neuroinflammatory condition in brain: Damaging and protective mechanisms , 2008, Neuroscience & Biobehavioral Reviews.

[182]  R. Drexhage,et al.  The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder , 2010, Expert review of neurotherapeutics.

[183]  S. Fatemi,et al.  The neurodevelopmental hypothesis of schizophrenia, revisited. , 2009, Schizophrenia bulletin.

[184]  Lin He,et al.  Convergent Evidence Shows a Positive Association of Interleukin-1 Gene Complex Locus with Susceptibility to Schizophrenia in the Caucasian population , 2010, Schizophrenia Research.